Molecular detection of CF lung pathogens: Current status and future potential

被引:19
|
作者
Pattison, Sally H. [1 ,2 ]
Rogers, Geraint B. [3 ]
Crockard, Martin [4 ]
Elborn, J. Stuart [1 ,2 ]
Tunney, Michael M. [1 ,5 ]
机构
[1] Queens Univ Belfast, CF & Airways Microbiol Res Grp, Belfast BT7 1NN, Antrim, North Ireland
[2] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland
[3] Kings Coll London, Mol Microbiol Res Lab, Inst Pharmaceut Sci, London SE1 9NH, England
[4] Randox Labs Ltd, Crumlin, Ireland
[5] Queens Univ Belfast, Sch Pharm, Belfast BT7 1NN, Antrim, North Ireland
关键词
Microbiology; Pathogen; Molecular; Detection; Identification; DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL SUSCEPTIBILITY; PULMONARY EXACERBATIONS; BACTERIAL DIVERSITY; IDENTIFICATION; PREVALENCE; CHILDREN;
D O I
10.1016/j.jcf.2013.01.007
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Molecular diagnostic tests, based on the detection and identification of nucleic acids in human biological samples, are increasingly employed in the diagnosis of infectious diseases and may be of future benefit to CF microbiology services. Our growing understanding of the complex polymicrobial nature of CF airway infection has highlighted current and likely future shortcomings in standard diagnostic practices. Failure to detect fastidious or slow growing microbes and misidentification of newly emerging pathogens could potentially be addressed using culture-independent molecular technologies with high target specificity. This review considers existing molecular diagnostic tests in the context of the key requirements for an envisaged CF microbiology focussed assay. The issues of assay speed, throughput, detection of multiple pathogens, data interpretation and antimicrobial susceptibility testing are discussed. (C) 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:194 / 205
页数:12
相关论文
共 50 条